Immunity and Immunotherapy in Inflammatory Bowel Diseases (IBD)

Dr Mandlik has been a researcher and lecturer for over 14 years. He is an Assistant Professor in the Department of Pharmaceutics, Bharati Vidyapeeth, Poona College of Pharmacy. Dr Mandlik’s research interests include: drug targeting, nanocarriers for drug delivery systems, and Quality by Design or QbD. Dr Mandlik holds the following degrees: M. Pharm, Ph.D (Pharmacology). Dr Mandlik has been a researcher and lecturer for over 10 years. Dr Mandlik’s research interests include: hepatoprotection; inflammation and immunity; gene transactivation and transrepression; anti-diabetic studies; and toxicity studies

• Part 1 Immunity in inflammatory bowel diseases1 Overview of inflammatory bowel diseases: from bench to bedside2 Pathophysiology of inflammatory bowel disease: innate immune system3 Understanding the intestinal epithelial barrier in IBD4 Role of innate and adaptive immunity in IBD5 Role of dendritic cells in pathogenesis of IBD6 Potential role of natural killer cells in pathogenesis of inflammatory bowel disease7 Immunobiology of T-Cells and B-Cells in inflammatory bowel disease8 Immunobiology of intestinal epithelial cells in inflammatory bowel disease9 Immunobiology of monocytes, macrophages, and polymorphonuclear Cells (PMN) in inflammatory bowel disease10 Cytokine networks in the pathophysiology of inflammatory bowel disease11 Role of chemokines in the pathophysiology of inflammatory bowel disease12 Transforming growth factor (TGF)-β, activins and follistatin: A key regulator in inflammatory bowel disease 14 Role of Occludin, Claudin-2, and Zonulin in inflammatory bowel diseasePart B Immunotherapy in inflammatory bowel diseases15 Basics of immunotherapy in inflammatory bowel disease16 Targeting tumor necrosis factor (TNF)-alpha in inflammatory bowel disease17 Integrin inhibition in inflammatory bowel disease18 Janus kinase (JAK) inhibitors in inflammatory bowel disease19 Stem cell and cell-based therapies in inflammatory bowel disease20 Interleukin inhibition: targeting cytokine pathways21 Key molecular targets for antisense therapy in inflammatory bowel disease22 Therapeutic approaches targeting sphingolipids in inflammatory bowel disease23 Tyrosine kinase inhibitors (TKIs) in inflammatory bowel disease: mechanisms and potential targets23 Tyrosine kinase inhibitors (TKIs) in inflammatory bowel disease: mechanisms and potential targets24 Immune checkpoint modulation as a therapeutic strategy in inflammatory bowel disease25 Potential targets for chimeric antigen receptor (CAR)-T cells in inflammatory bowel disease26 Personalized medicine in inflammatory bowel disease immunotherapy27 Advances in immunotherapy and emerging agents28 Immunotherapy resistance and management of failure in inflammatory bowel disease29 Safety, long-term outcomes, and side effects of immunotherapy30 Immunotherapy and the gut microbiome in inflammatory bowel disease